CXCL13 and acute myeloid leukemia: According to an in-vivo study, CXCL13 has been suggested as a novel IC regulating Breg activity where ablation of CXCL13 increased the efficacy of chemotherapy and PD-1 blockade, though this study did not involve an AML model (172).